Levin I, Klein T, Goldstein J, Kuperman O, Kanetti J, Klein B
Department of Urology, Soroka University Hospital, Beer Sheva, Israel.
Cancer. 1991 Dec 15;68(12):2591-4. doi: 10.1002/1097-0142(19911215)68:12<2591::aid-cncr2820681212>3.0.co;2-l.
The expression of class I histocompatibility antigens (HLA) in transitional cell carcinoma of the bladder was studied by the immunoperoxidase technique and correlated with tumor differentiation and survival. Tumors of 33 patients who underwent cystectomy were examined; 57% of the tumors expressed HLA class I antigens. Positive expression was observed in 5 of 6 cases with Grade 1 tumors, 8 of 13 with Grade 2, and 6 of 14 with Grade 3. The 5-year survival was significantly better in patients with HLA class I-positive tumors (74%) compared with those with negative tumors (36%, P less than 0.05). The expression of HLA class I on tumor cells may serve as a target for the immune response and control the metastatic potential of the tumor. These results suggest that HLA class I expression in bladder carcinoma is a prognostic indicator that should be considered in treatment planning.
采用免疫过氧化物酶技术研究了膀胱移行细胞癌中I类组织相容性抗原（HLA）的表达，并将其与肿瘤分化和生存率相关联。对33例行膀胱切除术患者的肿瘤进行了检查；57%的肿瘤表达I类HLA抗原。1级肿瘤6例中有5例观察到阳性表达，2级13例中有8例，3级14例中有6例。I类HLA阳性肿瘤患者的5年生存率（74%）明显高于阴性肿瘤患者（36%，P<0.05）。肿瘤细胞上I类HLA的表达可能作为免疫反应的靶点，并控制肿瘤的转移潜能。这些结果表明，膀胱癌中I类HLA的表达是一种预后指标，在治疗规划中应予以考虑。
